ASP3082, DEXTROSE INJECTION / BRADEX 5%
CSET 2025/4116
Phase 2 small_molecule active
Quick answer
ASP3082, DEXTROSE INJECTION / BRADEX 5% for Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active